SONN — Sonnet Biotherapeutics Holdings Income Statement
0.000.00%
Last trade - 00:00- $24.78m
- $24.46m
- $0.02m
Annual income statement for Sonnet Biotherapeutics Holdings, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.484 | 0.35 | 0.148 | 0.019 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 24.2 | 25.6 | 30 | 18.9 | 7.57 |
| Operating Profit | -24.2 | -25.1 | -29.7 | -18.8 | -7.55 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -24.3 | -25 | -29.7 | -18.8 | -7.44 |
| Net Income After Taxes | -24.3 | -25 | -29.7 | -18.8 | -7.44 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -24.3 | -25 | -29.7 | -18.8 | -7.44 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -65.6 | -25 | -29.7 | -18.8 | -7.44 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -15,375 | -2,508 | -1,203 | -145 | -17.9 |